Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Synopsis: In these 2 studies, the quadrivalent measles, mumps, rubella, and varicella (MMRV) vaccine, with increased potency of varicella compared to the current monovalent varicella vaccine, provides a varicella response rate of 81% and 91% after 1 dose, and 99% and 100% after 2 doses.

Immunogenicity and Safety of the New MMRV Vaccine